Programme Accès-recherche Dr André-Robidoux

Supported by a $2.5 million donation over 5 years from Breast Cancer Canada, the main objectives of the McPeak-Sirois Group’s Programme Accès-recherche Dr. André-Robidoux are to increase:

  • the number of Quebec hospitals participating in clinical studies, particularly in the regions;
  • the number of protocols in breast cancer offered by hospitals
  • access to clinical studies for patients who live outside of major urban centres.

In other words, it’s about bringing clinical research closer to patients while allowing them to stay in their region, close to their loved ones.

Our partner Breast Cancer Canada is a national charity dedicated to saving lives through breast cancer research.

The addition of hospitals to the consortium contributes to the emergence of a multi-institutional network that promotes a greater number of research protocols to be attributed to the Group and fosters attractiveness to pharmaceutical companies and other collaborative groups that fund these studies.

A win-win situation that ultimately benefits patients, as Kimberly Carson, CEO of Breast Cancer Canada, points out:

“Together, we are expanding access to clinical trials and reaching more Canadian breast cancer patients. This partnership represents a significant step forward in our ongoing mission to improve outcomes and transform the breast cancer landscape so it is personalized to each individual.”

“This funding will lead to substantial growth for our consortium, enabling the expansion of clinical trial offerings across the province of Quebec. As a former patient and clinical trial participant myself, I know how important it is to be given access to research that cares, regardless of where you live.” says Susan McPeak, co-founder of the McPeak-Sirois Group.

The Programme Accès Recherche Dr. André-Robidoux was launched in 2016 by the Group and funded from 2017 to 2022 thanks to a $1.4 million donation from the Quebec Breast Cancer Foundation.  During this period, six hospitals joined our Group.